Spanish version of the Mattis Dementia Rating Scale-2 for early detection of Alzheimer's disease and mild cognitive impairment

被引:2
作者
Boycheva, Elina [1 ]
Contador, Israel [2 ]
Fernandez-Calvo, Bernardino [3 ]
Ramos-Campos, Francisco [4 ]
Puertas-Martin, Veronica [5 ]
Villarejo-Galende, Alberto [5 ]
Bermejo-Pareja, Felix [1 ,6 ]
机构
[1] Univ Hosp 12 Octubre i 12, Clin Res Unit, Madrid, Spain
[2] Univ Salamanca, Dept Basic Psychol Psychobiol & Methodol Behav Sc, Salamanca, Spain
[3] Univ Fed Paraiba, Dept Psychol, Joao Pessoa, Paraiba, Brazil
[4] Univ Salamanca, Dept Personal Assessment & Psychol Treatment, Salamanca, Spain
[5] Univ Hosp 12 Octubre, Dept Neurol, Madrid, Spain
[6] Univ Complutense Madrid, Fac Med, Madrid, Spain
关键词
mild cognitive impairment; Alzheimer's disease; early detection; neuropsychological assessment; clinical validity; older adults; MENTAL-STATE-EXAMINATION; NEURONORMA PROJECT NORMS; BOSTON NAMING TEST; NORMATIVE DATA; CLINICAL VALIDITY; PARKINSONS-DISEASE; PREMORBID INTELLIGENCE; FUNCTIONAL-ACTIVITIES; CHINESE VERSION; OLDER-ADULTS;
D O I
10.1002/gps.4707
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
ObjectiveWe aimed to analyse the clinical utility of the Mattis Dementia Rating Scale (MDRS-2) for early detection of Alzheimer's disease (AD) and amnestic mild cognitive impairment (MCI) in a sample of Spanish older adults. MethodsA total of 125 participants (age=75.126.83, years of education =7.083.57) were classified in three diagnostic groups: 45 patients with mild AD, 37 with amnestic MCIsingle and multiple domain and 43 cognitively healthy controls (HCs). Reliability, criterion validity and diagnostic accuracy of the MDRS-2 (total and subscales) were analysed. The MDRS-2 scores, adjusted by socio-demographic characteristics, were calculated through hierarchical multiple regression analysis. ResultsThe global scale had adequate reliability (=0.736) and good criterion validity (r=0.760, p<.001) with the Mini-Mental State Examination. The optimal cut-off point between AD patients and HCs was 124 (sensitivity [Se]=97% and specificity [Sp]=95%), whereas 131 (Se=89%, Sp=81%) was the optimal cut-off point between MCI and HCs. An optimal cut-off point of 123 had good Se (0.97), but poor Sp (0.56) to differentiate AD and MCI groups. The Memory and Initiation/Perseveration subscales had the highest discriminative capacity between the groups. ConclusionsThe MDRS-2 is a reliable and valid instrument for the assessment of cognitive impairment in Spanish older adults. In particular, optimal capacity emerged for the detection of early AD and MCI. Copyright (c) 2017 John Wiley & Sons, Ltd.
引用
收藏
页码:832 / 840
页数:9
相关论文
共 91 条
  • [1] Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease
    Aarsland, D
    Litvan, I
    Salmon, D
    Galasko, D
    Wentzel-Larsen, T
    Larsen, JP
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (09) : 1215 - 1220
  • [2] [Anonymous], 2005, Programa Integrado de Evaluacion Neuropsicologica. Test de Barcelona
  • [3] BALDERESCHI M, 1994, NEUROLOGY, V44, pA365
  • [4] Bank AL, 2000, CLIN NEUROPSYCHOL, V14, P149, DOI 10.1076/1385-4046(200005)14:2
  • [5] 1-Z
  • [6] FT149
  • [7] Is the Mattis Dementia Rating Scale appropriate to detect Mild Cognitive Impairment?
    Belaus, Anabel
    Fernandez, Luis A.
    Farias-Sarquis, Yamila
    Bueno M, Adrian M.
    [J]. REVISTA CHILENA DE NEUROPSICOLOGIA, 2015, 10 (01): : 8 - 13
  • [8] Benton A., 1989, MULTILINGUAL APHASIA
  • [9] Clinical Validity of the Mattis Dementia Rating Scale in Differentiating Mild Cognitive Impairment in Parkinson's Disease and Normative Data
    Bezdicek, Ondrej
    Michalec, Jiri
    Nikolai, Tomas
    Havrankova, Petra
    Roth, Jan
    Jech, Robert
    Ruzicka, Evzen
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2015, 39 (5-6) : 303 - 311
  • [10] Predicting Alzheimer dementia in mild cognitive impairment patients - Are biomarkers useful?
    Borroni, Barbara
    Di Luca, Monica
    Padovani, Alessandro
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 545 (01) : 73 - 80